Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer and Acura Announce FDA Approval of Oxecta

By Pharmaceutical Processing | June 20, 2011

 

Pfizer Inc. and Acura Pharmaceuticals Inc. announce the
marketing approval from the FDA of OXECTA (oxycodone HCl, USP) Tablets CII.
OXECTA is indicated for the management of acute and chronic moderate to severe
pain where the use of an opioid analgesic is appropriate.

OXECTA is the first immediate-release oxycodone HCl medicine
that applies technology designed to discourage common methods of tampering associated
with opioid abuse and misuse. This AVERSION(R) Technology is a unique
composition of commonly used pharmaceutical ingredients.

Pfizer is licensing the technology in OXECTA from Acura.

Opioid medications are an important treatment option for
patients with moderate to severe pain who are not adequately managed by other
pain treatments. However, abuse and misuse of opioids is a serious public health
issue that is the focus of a number of recent United States government
initiatives.

“We recognize our responsibility to physicians and
patients and remain committed to appropriate access to pain treatment and
developing medicines to potentially address this important public health and safety
issue,” said Olivier Brandicourt, Pfizer president and general manager,
Primary Care. “OXECTA will further expand Pfizer’s presence in pain
management and complements our growing, robust portfolio of treatments and
medicines in development for pain relief, one of our strategic, high-priority
disease areas. We are pleased to bring OXECTA to patients and physicians with
our partner Acura.” “We are excited to be partnered with Pfizer to
bring OXECTA to patients who need opioids to manage their pain,” said
Robert Jones, interim president and chief executive officer of Acura Pharmaceuticals,
Inc. “Acura is focused on developing technologies that are intended to
potentially deter abuse and misuse.”  

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards